Prosight Management, LP Reata Pharmaceuticals Inc Transaction History

Prosight Management, LP

$372 Million
Q3 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$94.25 - $132.81 $1.14 Million - $1.61 Million	-12,112 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$102.03 - $184.62 $10.5 Million - $18.9 Million	-102,442 Reduced 89.43%	12,112 $1.5 Million
Q3 2020 Nov 13, 2020	BUY	$93.53 - $163.34 $3.04 Million - $5.3 Million	32,454 Added 39.53%	114,554 $11.2 Million
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $896,730 - $1.25 Million	7,100 Added 9.47%	82,100 $12.8 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $1.5 Million - $3 Million	12,100 Added 19.24%	75,000 $10.8 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $23,042 - $67,337	309 Added 0.49%	62,900 $12.9 Million
Q3 2019 Nov 14, 2019	SELL	$71.26 - $95.75 $4.44 Million - $5.97 Million	-62,374 Reduced 49.91%	62,591 $5.03 Million
Q2 2019 Aug 14, 2019	SELL	$77.72 - $94.35 $3.94 Million - $4.79 Million	-50,735 Reduced 28.88%	124,965 $11.8 Million
Q1 2019 May 15, 2019	SELL	$51.9 - $101.79 $4.01 Million - $7.87 Million	-77,300 Reduced 30.55%	175,700 $15 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $76.44 $8.43 Million - $13.2 Million	172,845 Added 215.64%	253,000 $14.2 Million
Q3 2018 Nov 15, 2018	SELL	$35.64 - $92.06 $104,745 - $270,564	-2,939 Reduced 3.54%	80,155 $6.55 Million
Q2 2018 Aug 14, 2018	SELL	$19.94 - $40.96 $4.28 Million - $8.79 Million	-214,656 Reduced 72.09%	83,094 $2.91 Million
Q1 2018 May 14, 2018	BUY	$20.0 - $30.19 $2.5 Million - $3.77 Million	124,853 Added 72.21%	297,750 $6.11 Million
Q4 2017 Feb 13, 2018	BUY	$22.39 - $33.27 $3.87 Million - $5.75 Million	172,897	172,897 $4.9 Million

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Prosight Management, LP with notifications on news.

Account